title: New Therapy for Spinal Muscular Atrophy Offers Modest Bang for Pharamaceutical Buck.
abstract: Spinraza is a breakthrough, no doubt. It is a survival SMN-2-directed antisense oligonucleotide indicated for the treatment of SMA in pediatric and adult patients and is administered by injections into the spinal fluid (intrathecally). But it is another ultraexpensive drug, and the evidence so far points to a modest improvement in motor milestones.
authors.forename: Thomas
authors.initials: T
authors.lastname: Morrow
mesh_terms: D003362:Cost-Benefit Analysis; D006801:Humans; D009134:Muscular Atrophy, Spinal / Q000188:drug therapy* / Q000235:genetics; D009841:Oligonucleotides / Q000191:economics* / Q000494:pharmacology / Q000627:therapeutic use; D016376:Oligonucleotides, Antisense / Q000187:drug effects
chemical_list: D009841:Oligonucleotides; D016376:Oligonucleotides, Antisense; C000590926:nusinersen